Sequenom, Inc. (NASDAQ:SQNM)

CAPS Rating: 3 out of 5

A genetics company committed to providing genetic analysis products and services that translate genomic science into superior solutions for the biomedical research, molecular medicine, agricultural, and non-invasive prenatal testing markets.

Recs

3
Player Avatar mrindependent (95.81) Submitted: 11/18/2009 2:15:08 PM : Outperform Start Price: $3.23 SQNM Score: +29.45

Apparently Sequenom's reported success for non-invasive prenatal testing was based on improperly supervised studies. Now no one at the company is willing to guarantee success, but management is willing to say that they still believe in the science. The current Directors and Officers seem to be reputable experts in their fields and they do not seem to be con artists. Based on the people involved, the theoretical underpinings and on the promising (but suspect) data delivered so far, I believe that Sequenem has a better than even chance of eventually commercializing its tests (or or selling itself to a larger player). If the tests are indeed viable, this company will be worth billions compared to its current market cap of $200 million. In summary, I think reward outweights risk in this highly speculative stock that is currently trading at 1.8 times book value (which is 85% off its all time high).

Featured Broker Partners


Advertisement